Johns Hopkins University cancer researcher Mikala Egeblad has received the 2025 Ernst W. Bertner Memorial Award in ...
The complex tumor microenvironment (TME) in osteosarcoma is emerging as a critical factor in disease progression and treatment resistance. Recent insights highlight the intricate interplay between ...
Cancer immunotherapy is a type of cancer treatment that harnesses the immune system to fight cancer cells. The treatment ...
Large BIDMC-led study maps immune cells in myeloma tumors, improving risk prediction beyond genetics and helping identify ...
Head and neck cancer (HNC) remains a significant global healthcare challenge, characterized by persistently high incidence and mortality rates. Despite ...
On the one hand, circadian rhythm disorder contributes to tumor growth and metastasis by influencing the dysregulation of gene expression affecting the tumor itself. On the other hand, circadian ...
Efficacy and safety of regorafenib combined with immune checkpoint inhibitors in advanced hepatocellular carcinoma patients progressing after lenvatinib treatment. This is an ASCO Meeting Abstract ...
The field of regulated cell death has undergone a transformative shift with the discovery of novel modalities beyond apoptosis, such as ferroptosis, which ...
Over the past decade, the advent of immune checkpoint blockade (ICB) therapy has transformed cancer treatment. Unlike conventional cytotoxic and targeted therapies, immunotherapy leverages both the ...
Recent advances in cancer treatment highlight the potential of natural medicines to target the tumor vascular microenvironment, offering a novel strategy to inhibit tumor growth and metastasis. Unlike ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results